HCW Biologics (HCWB) Stock Statistics & Valuation Metrics

HCW Biologics has a market cap or net worth of $2.21M. The enterprise value is $5.54M.

HCW Biologics has 6,734,104 shares outstanding. The number of shares has decreased by -2.65% in one year.

HCW Biologics’s return on equity (ROE) is -8.07 and return on invested capital (ROIC) is -109.65%.

The current PE Ratio of HCW Biologics is ―. HCW Biologics’s PEG ratio is -0.00007.

In the last 12 months, HCW Biologics had revenue of 54.23K and earned -7.96M in profits. Earnings per share was -10.63.

In the last 12 months, operating cash flow was -13.39M and capital expenditures 0.00, giving a free cash flow of -13.39M billion.

HCW Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

HCW Biologics upcoming earnings date is May 7, 2026, Before Open (Confirmed).

HCW Biologics as a current ratio of 0.11, with Debt / Equity ratio of 246.29%

In the past 12 months, HCW Biologics has paid 0.00 in taxes.

HCW Biologics EV to EBITDA ratio is -1.22, with an EV/FCF ratio of -0.51.

HCW Biologics has $1.95M in cash and marketable securities with $6.81M in debt, giving a net cash position of -$4.86M billion.

Gross margin is -300.67%, with operating margin of -24270.74%, and net profit margin of -41117.24%.

The average price target for HCW Biologics is $2.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy